GOSSAMER BIO INC (GOSS) is drawing unusual attention today. Our newswire has captured 1 story on GOSS across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100).
Gossamer Bio (GOSS) shares are rising today following key developments regarding the regulatory path for its lead drug candidate, seralutinib, and the reacquisition of global rights to the therapy. The company announced that the FDA has outlined a potential timeline for a September 2026 New Drug Application (NDA) filing. Additionally, Gossamer Bio has regained full control of seralutinib, which is expected to enhance its strategic flexibility and strengthen its capital position.
The company filed a Form 8-K with the SEC on July 27, 2026, disclosing the reacquisition of worldwide rights to seralutinib and outlining a clear regulatory path forward. This development follows feedback from the FDA, which has provided guidance that could lead to an NDA submission by September. Leerink upgraded the stock rating based on this regulatory progress. The company also announced a restructuring of its debt and secured major investor approvals, which contributed to the positive market reaction.
GOSS has a market cap of $66.5 million and has been unprofitable, with a trailing twelve-month (TTM) net margin of -324.8% and an EPS of -0.78. The stock has declined by 17.0% over the last 8 trading sessions, moving from $0.22 to $0.18. Its 52-week range is between $0.11 and $3.87. The stock has a beta of 2.04, indicating higher volatility compared to the market. The recent news appears to have shifted investor sentiment, with the stock showing strength after the announcements.
The company has not provided an upcoming earnings date. Investors should monitor the breadth of coverage and any further regulatory updates related to seralutinib as the FDA timeline unfolds.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy.
GOSSAMER BIO INC (GOSS) is drawing unusual attention today. Our newswire has captured 1 story on GOSS across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100). The most recent driver: "Gossamer Bio shares jump after FDA update and seralutinib rights return" (Yahoo Top).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GOSS coverage reads 73/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on GOSS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GOSS move explainers: 2026-07-28 · 2026-07-27